Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy? by Paolo Fuzio et al.
Fuzio et al. BMC Cancer  (2015) 15:349 
DOI 10.1186/s12885-015-1348-0RESEARCH ARTICLE Open AccessClusterin transcript variants expression in thyroid
tumor: a potential marker of malignancy?
Paolo Fuzio1, Anna Napoli2, Anna Ciampolillo3, Serafina Lattarulo3, Angela Pezzolla3, Nicoletta Nuzziello1,
Sabino Liuni1, Francesco Giorgino3, Eugenio Maiorano2 and Elda Perlino1*Abstract
Background: Clusterin (CLU) is a ubiquitous multifunctional factor involved in neoplastic transformation. The CLU
transcript variants and protein forms play a crucial role in balancing cells proliferation and death.
Methods: We investigated the regulation of CLU transcript variants expression in an in vivo model system
consisting of both neoplastic tissues and fine needle aspiration biopsy (FNAB) samples isolated from patients
undergoing thyroidectomy.
Results: The immunohistochemical analyses showed an overall CLU up-regulation in papillary carcinoma. A specific
CLU2 transcript variant increase was registered using qPCR in papillary carcinomas while CLU1 decreased. In
addition, the analysis of CLU transcripts expression level showed an increase of the CLU2 transcript in the TIR 3
patients with histologically confirmed thyroid cancer.
Conclusions: Our results suggest the existence of a specific alteration of CLU2:CLU1 ratio towards CLU2, thus
providing the first circumstantial evidence for the potential use of CLU transcript variants as effective biomarkers for
a more accurate assessment of the so called “indeterminate” thyroid nodules.
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Thyroid nodules are extremely common most of them
are not cancerous, while malignant lesions derived from
thyroid epithelial cells are relatively rare. The initial
evaluation of thyroid nodules commonly involves thyroid
function tests, ultrasound examination (USG) and fine
needle aspiration biopsy (FNAB) of selected nodules.
Clinically recognized thyroid carcinomas constitute 5-7%
of all thyroid nodules and 1% of all human malignant
tumours. The annual incidence of thyroid cancer varies
worldwide from 0.5 to 10 per 100,000.
Thyroid carcinoma usually originates from follicular
cells, and medullary carcinoma, which is a form of
thyroid cancer, originates from the parafollicular C cells.
Distinct histological types of follicular cell-derived can-
cers (FCDC) are recognized: the majority of cases are
papillary, including its major subtype follicular variant* Correspondence: elda.perlino@ba.itb.cnr.it
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unless otherwise stated.(FVPTC); the remaining are follicular, oxyphilic or
Hurthle cell, poorly differentiated and anaplastic carcin-
omas. Such tumour subtypes substantially differ from
each other in terms of propensity to recurrence, distant
spread and metastatic involvement [1,2].
Over the past 15 years, the application of molecular
technologies to the study of these neoplasms has
revealed critical genetic pathways associated with the
development of specific thyroid tumour types [3]. The
results obtained from several studies have shown that
the progression from a single normal cell to a fully ma-
lignant phenotype requires both the activation of onco-
genes and the inactivation of tumour suppressor genes.
Furthermore, signals from paracrine and/or autocrine
pathways, alone or in combination, may regulate these
processes, the final effects depending on the net balance
between stimulatory and inhibitory factors. As the tumour
progresses, neoplastic cells often lose the inhibitory
growth factors in the regulation of cell proliferation, while
the expression of positive autocrine growth factors in-
creases. In this regard, the aberrant expression or functionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hesion factors, growth factors, apoptotic factors and their
receptors, invariably occurs in several cancers, including
thyroid carcinoma [4]. Among these, Clusterin (CLU) may
represent a target gene that can be used to monitor
changes that are responsible for the progression from nor-
mal to malignant and metastatic tissue.
CLU is a glycoprotein with a slightly ubiquitous tissue
distribution and an apparent involvement in biological
processes ranging from neurodegeneration in Alzheimer’s
disease to cancer initiation and progression [5,6]. Indeed,
CLU has been implicated in numerous physiologic and
pathologic processes important for carcinogenesis and
tumour growth, including apoptotic cell death, cell cycle
regulation, DNA repair, cell adhesion, tissue remodeling,
lipid transportation, membrane recycling and immune
system regulation [5,6]. Understanding the different func-
tions of CLU has been an elusive goal, as it its processes
are of very different nature and sometimes contradictory.
This ambiguity is partly due to the existence of two func-
tionally divergent protein forms: a glycosylated secreted
heterodimer of approximately 80 kDa (sCLU) and a
55 kDa non-glycosylated nuclear form (nCLU). sCLU is
the secreted heterodimer with documented anti-apoptotic
function, while nCLU was reported to move from the
cytoplasm to the nucleus following certain cytotoxic
events and postulated to induce apoptosis [7]. The nCLU
protein form can be synthesized from a second in-frame
AUG codon and does not undergo cleavage or extensive
glycosylation. Recent studies provide strong evidence for
an anti-apoptotic function for sCLU [8], even though pre-
cise site(s) of action and binding proteins remain poorly
defined. This study suggested that elevated levels of CLU
in several human cancers might promote tumour progres-
sion by interfering with pro-apoptotic pathways by inter-
action with activated Bax, thereby inhibiting cytochrome
C release and apoptosis [8]. The biology of CLU is how-
ever even more complex. Indeed, analogous to the two
forms of Bcl-x that arise from alternative splicing, with the
long form having anti-apoptotic and the short form having
pro-apoptotic properties, the mature sCLU has a cyto-
protective function, while under certain conditions pro-
apoptotic signals may induce the expression of the
nCLU protein forms [9,10].
Recent studies have demonstrated there is no relation-
ship between CLU transcript variants and CLU protein
forms, showing as CLU1 and CLU2 code for the same
secreted protein (sCLU) also identical regarding the
post-transcriptional modifications (i.e. glycosylation) [11,12].
However, the characterization of CLU and its functional
role have not been clearly established yet.
Increased expression of CLU has been found in differ-
ent diseases where either abnormal cell death or prolifer-
ation occurs [13]. Moreover, CLU mRNA and proteinwere found over-expressed in several human cancers
such as prostate, breast, lung, kidney, ovarian, colon,
and endometrial tissues [14-22]. These findings indicate
that CLU is a cell survival gene up-regulated by apoptotic
triggers, and when over-expressed may confer resistance
to apoptosis, representing a potential therapeutic target
for cancer. In preclinical models of prostate cancer, in fact,
CLU antisense oligonucleotides improved the efficacy of
chemotherapy, radiation therapy, and androgen withdrawal
by enhancing the apoptotic response [23].
CLU was identified by microsequencing in the culture
medium of porcine thyrocytes [24]. Treatment of thyro-
cytes with thyroid stimulating hormone (TSH) revealed
a tight regulation of both synthesis and secretion of
CLU, with a distinct fraction of CLU being always asso-
ciated with the cells. The association with the apical
plasma membrane, which carries the iodinating system
in thyrocytes, was confirmed by biosynthetic iodination
and CLU was found within distinct, bipartite patches,
suggesting that it is a constituent of cell-adhesion
complexes and participates in cell-cell and cell-matrix
interactions [24].
A large number of genes, which are regulated by the
thyroid, can be potentially used as marker genes for can-
cer diagnosis and prognosis. Previous data suggested
that CLU expression in thyroid malignant cells was
modified in vitro and in vivo, and that there was a com-
plex mechanism of regulation of CLU expression in the
normal and cancerous thyroid tissue [25,26].
Changes in CLU expression may thus play a role in the
pathogenesis of the thyroid malignant transformation. In
this light, we measured the CLU expression at mRNA and
protein level in neoplastic and non-neoplastic thyroid
tissues, to assess the potential role of CLU as a biomarker
for thyroid cancer.
Moreover, we investigated potential changes in CLU
expression in fine needle aspiration biopsy (FNAB) of
thyroid nodules with indeterminate (TIR 3) cytology to
assess the potential use of CLU as a biomarker to
discriminate between benign and malignant lesions, thus
obtaining relevant information to select the patients to
submit to thyroidectomy for malignancy.
Results
CLU immunohistochemistry
CLU immunoreactivity was evaluated in 50 thyroid tissues
isolated from patients with adenoma (n = 40) and papillary
carcinoma (n = 10).
Figure 1 shows the Hematoxylin-Eosin and the im-
munohistochemical microscopic features of a follicular
adenoma (A and B, respectively) and a papillary carcin-
oma (C, D). Anti-CLU antibody clearly highlights posi-
tive staining in the cytoplasm of thyrocytes in all
sections, according to previously reported findings on
Figure 1 CLU immunohistochemical analyses. (A) Hematoxylin-Eosin staining of a follicular adenoma. (B) Anti-CLU antibody immunostaining of
the same adenoma. (C) Hematoxylin-Eosin staining of a papillary carcinoma with adjacent normal thyroid tissue. (D) Anti-CLU antibody
immunostaining of the same carcinoma. (E) Immunoreactive epithelial cells in thyroid carcinomas (K, n = 10) and thyroid adenomas (A, n = 40)
samples, respectively.
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tissues [14,18,19].
Figure 1E shows the percentage of CLU immunoreactive
cells in thyroid adenomas (A) and papillary carcin-
omas (K) respectively. The average percentage of CLU-
immunoreactive cells was much higher (almost 6 fold) in
papillary thyroid carcinomas than in thyroid adenomas.
Comparable results were obtained with both the anti-
bodies used, with less than 5% variation in the percentage
of immunoreactive cells of each sample. These results sug-
gest that CLU-immunoreactivity is detectable in a much
higher number of neoplastic cells in papillary thyroid
carcinomas in comparison with adenomas.
Analysis of CLU mRNA variants
Since antibodies specific to each of the CLU protein
forms are not available, we could not evaluate the differ-
ent protein CLU variants but the α subunit of the CLU
heterodimer was recognized by the (Clone 41D) anti-
body that is a monoclonal anti-human CLU. In this light,the different CLU transcript variants expressed in the
thyroid tissues were evaluated by qPCR. To identify all
possible novel CLU transcript variants, we first inspected
the CLU entries in the ASPicDB, the Alternative Splicing
Prediction Data Base (http://srv00.ibbe.cnr.it/ASPicDB/)
[27,28]. These inspections revealed multiple possible
CLU transcript variants, two of which identified by the
Signature ID [29] c7175b345e:9 and 1057fea355:9, over-
lapping to the sequences of the NCBI database with ac-
cession number NM_001831, CLU1 and NR_038335,
CLU2. These two variants all contain nine exons, and
each of them presents a unique exon 1 and shares the
remaining 2–9 exons [21]. Although the CLU1 transcript
variant was not present in other cancer tissues [11,30]
the reason why it is taken into consideration is because
it stood out by having substantially more sequence sup-
port than the others in the ASPicDB in silico analysis.
By RT-PCR analysis followed by sequencing experi-
ments, the two CLU transcript variants were found to be
expressed in the human thyroid tissues. Moreover, by
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were detected except the two variant-specific RT-PCRs
(data not shown).
Moreover, potential quantitative changes in CLU tran-
script variants expression were investigated by means of
qPCR as reported in Materials and Methods in the thy-
roid tumour tissues in comparison to the corresponding
normal tissues isolated from the same patients (see
Table 1). Raw fluorescence data were normalized with
respect to the GAPDH expression level in all samples
and the CLU transcript variants expression obtained in
thyroid tumour samples was normalized to the corre-
sponding normal samples.
The CLU1 expression level was almost 4-fold higher
in the thyroid cancer tissues than in the normal thyroidTable 1 Clinical features of patients affected by thyroid carcin
Patients Age (years) Gender Histology
N1 26 Female Normal Thyroid
K1 Papillary Thyroid
N2 60 Male Normal Thyroid
K2 Papillary Thyroid
N3 58 Female Normal Thyroid
K3 Papillary Thyroid
N4 60 Male Normal Thyroid
K4 Papillary Thyroid
N5 37 Male Normal Thyroid
K5 Follicular Thyroid
N6 58 Male Normal Thyroid
K6 Follicular Thyroid
N7 - Female Normal Thyroid
K7 Papillary Thyroid
N8 - Female Normal Thyroid
K8 Papillary Thyroid
N9 - Female Normal Thyroid
K9 Follicular Thyroid
N10 - Female Normal Thyroid
K10 Follicular Thyroid
N11 38 Female Normal Thyroid
K11 Thyroid Adenoma
N12 50 Female Normal Thyroid
K12 Thyroid Adenoma
N13 72 Male Normal Thyroid
K13 Thyroid Adenoma
N14 79 Female Normal Thyroid
K14 Thyroid Adenoma
N55 - Female Normal Thyroid
K15 Thyroid Adenoma
- : data unknown.tissues (Figure 2A). The CLU2 expression level was also
markedly elevated (10-fold) in the thyroid cancer tissues
in comparison to the normal thyroid tissues (Figure 2B).
Since it has been suggested that the CLU2:CLU1 cellu-
lar balance may be critical for cancer development and
progression [31], the analysis of the ratio of the two
transcript variants was investigated. The relative concen-
tration of CLU2:CLU1 transcript variants in tumour
samples shows a down regulation of the CLU1 expres-
sion. Using the CLU1 level as calibrator arbitrarily set as
100%, the CLU2 expression resulted higher (185% ± 15)
than CLU1 (Figure 2C).
Even though the statistical analysis is not sufficiently
reliable, due to the limited number of investigated cases
with different TNM staging (T1, n = 3; T2, n = 3; T3,oma































Figure 2 CLU mRNA variants analyses. CLU transcript variants levels of malignant tissues (KT) compared to normal thyroid (NT). (A) CLU1
expression level. (B) CLU2 expression level. (C) CLU2 expression compared to CLU1, arbitrarily setted as 100%.
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Figure 3 CLU mRNA variants analyses according to the SIAPEC
cytological classification. CLU2 and CLU1 expression in the TIR3 (A)
and TIR4 + TIR5 (B) neoplastic thyroid samples, compared to normal
thyroid tissues (NT). Data are expressed according to the histological
diagnosis after surgery. (C) CLU2 expression in TIR3 thyroid samples
according to histological classification (i.e., benign vs. malignant)
after surgery. CLU2 expression was compared to CLU1, arbitrarily
setted as 100%.
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potential shift in the CLU transcript variants expres-
sion from the pro-apoptotic CLU1 protein forms to
the cytoprotective-oncogenic CLU2 protein form dur-
ing the transition from normal to malignant cells.
CLU transcript variants expression in the indeterminate
thyroid nodules
The absence of biomarkers which could be used in case
of indeterminate tumors (i.e., TIR3) to support the clini-
cian’s decision to recommend surgery, represents one of
the most debated issues in the management of thyroid
nodules. In this light, we investigated the balance be-
tween the two CLU transcript variants in thyroid nod-
ules with different cytological diagnosis following fine
needle aspiration biopsy (FNAB) (see Table 1), and spe-
cifically TIR 3 (indeterminate), TIR 4 (suspicious) and
TIR 5 (malignant), according to the SIAPEC cytological
classification [32]. We also compared the results to the
histological diagnosis after surgery, to assess whether the
lesions were benign or malignant. Regardless of the
benign or malignant nature, after the histological test,
CLU2 expression was always higher than CLU1 in all
TIR 3 (242 ± 25%) and TIR 4 + TIR 5 (233 ± 21%) malig-
nant thyroid tissues samples (Figures 3A and B) and this
increase was always statistically significant (p < 0.05).
Our results show a shift of the CLU2:CLU1 ratio in
favour of CLU2 in both TIR3 and TIR4 + TIR5 cyto-
logical samples with a histologically proved diagnosis of
malignancy.
Figure 3C shows CLU2 expression levels measured in
TIR3 samples, according to histological classification
obtained after surgery (i.e., benign vs. malignant) in
comparison to the CLU1 expression used as control.
Histology indicated a benign lesion in 4/8 of the TIR3
samples and a malignant lesion in the remaining 4
samples. In the benign TIR3 thyroid tissues, CLU2 ex-
pression levels were lower than CLU1 level (73 ± 20%,
p < 0.05). On the contrary, in the malignant TIR3
thyroid tissues, CLU2 expression levels were higher
than CLU1 levels (410 ± 30%, p < 0.05).
In conclusion, these results show an increase of CLU2
in malignant thyroid tissues, suggesting a possible use of
this transcript variant to discriminate between those
TIR3 (indeterminate) cases proven malignant at histo-
logical examination and those diagnosed as benign
nodules.
CLU transcript variants expression in thyroid fine-needle
aspiration
Finally, we measured the transcript levels of the two
CLU transcript variants in the FNAB samples of 15
patients (K1-K15) with indeterminate thyroid nodules
cytology (see Table 1) to verify the potential diagnosticuse of CLU to pre-operatively discriminate among pa-
tients undergone a thyroidectomy for malignancy. In the
FNABs samples CLU2 expression was higher than CLU1
(185% ± 15; p < 0.05; data not shown) as already shown
in thyroid tissues.
In the TIR3 and TIR4 + TIR5 FNAB cytological sam-
ples, CLU2 expression levels were higher than CLU1
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not shown) suggesting a shift in the CLU2:CLU1 ratio
in favour of the CLU2 transcript variant, thus confirm-
ing the results obtained in the thyroid tissues.
The CLU transcript variants expression level was also
measured in TIR3 samples classified according to their
benign or malignant nature, as determined by histo-
pathological examination (Figure 4). In histologically
benign TIR3 FNABs, the CLU2 transcripts level was
always lower than CLU1 transcripts level (ranging from
31 ± 7% to 81 ± 8%; average value = 47 ± 10%; p < 0.05).
On the contrary, in histologically malignant TIR3
FNABs, CLU2 levels were higher than CLU1 levels
(ranging from 175 ± 11% to 306 ± 12%; average value =
229 ± 20%; p <0.05).
The usefulness of the ratio of CLU2:CLU1 expression
to distinguish the malignant thyroid tumors from aden-
oma in patients with TIR3 thyroid FNAB lesions was
evaluated using receiver operating curve (ROC) analysis
performed by MedCalc Statistical Software. Although
our results will be verified on a larger population, the
AUC was 1.00 with 100% specificity and 100% sensitivity
(Figure 4B).
In conclusion, our results suggest a specific increase of
CLU2 in TIR3 thyroid FNAB lesions which were found
to be malignant at histological examination, suggesting a
possible role of the CLU2 transcript variant to discrimin-
ate between those cytologically indeterminate (TIR3)
lesions that were histologically diagnosed as benign or
malignant, thus potentially supporting the clinician’s
decision to operate on these patients.
Discussion
Although several molecules are associated with thyroid
carcinogenesis, their role in malignant transformation
has not been well established yet. Over the past 15 years,Figure 4 CLU2 expression in the TIR3 FNAB samples classified according to
to CLU1, arbitrarily setted as 100%. (B) ROC curve analysis showed the usef
the malignant thyorid tumors from adenoma in patients with TIR3 thyorid FNthe application of molecular technologies to the study of
this neoplasm has revealed critical genetic pathways
associated with the development of specific thyroid
tumour subtypes.
Despite the growing evidence of the role of CLU in
the aetiology of cancer in several tissues, the regulation
of its expression and functions in human thyroid carcin-
oma has not been investigated.
As already mentioned, CLU is expressed by thyrocytes
and undergoes a TSH-dependent regulation [24]. Fur-
thermore, CLU may influence cellular apoptosis in neo-
plastic cells, as recently shown in retinoblastoma cells,
in which overexpression of CLU was associated with
enhanced cellular apoptosis [33].
In order to assess the possible role of this gene as a
candidate biomarker for thyroid cancer, we investigated
CLU transcript variants in neoplastic and non-neoplastic
thyroid tissues by measuring protein and transcript ex-
pression by immunohistochemical and qPCR techniques.
Immunohistochemical analysis showed an overall up-
regulation of CLU protein expression in papillary carcin-
oma. The prevalent CLU protein expression in the
thyroid carcinoma, in agreement with results from other
laboratories, suggests that CLU may play a cytoprotec-
tive role in mammalian epithelia, including thyroid,
oesophagus, urethra and rete testis epithelial cells [3].
The results from this study are also in agreement with
the findings showing increased CLU transcript variants
expression in hormonally regulated human cancers, such
as prostate and breast carcinomas [10,14]. In both cases,
CLU up-regulation was associated with increased cancer
cell survival, suggesting that CLU over-expression may
contribute to increased tumour cell survival. We found
here for the first time that the two CLU transcript
variants are expressed in thyroid tissues and that CLU
transcript expression is up-regulated in vivo.the histopathological diagnosis. (A) CLU2 expression was compared
ulness of the ratio of CLU2:CLU1 expression for clearly distinguishing
AB lesions. MedCalc statistical software was used for statistical analysis.
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most 4-fold higher than in normal thyroid. Furthermore,
CLU2 transcripts expression level resulted markedly in-
creased (12-fold) in thyroid cancer tissues, in compari-
son with normal thyroid tissues.
Since it has been suggested that the CLU2:CLU1 cellu-
lar balance may be critical for cancer initiation and pro-
gression, an analysis on the ratio of transcripts level
encoding each of the two CLU1 and CLU2 variants in
the thyroid tissues was carried out. This is the first time
that statistically significant variations in the CLU2:CLU1
ratio in papillary carcinoma have been found, confirming
similar findings in other tumors, such as prostate [18],
breast [14], lung [17], colon [16], and ovary [19] cancers,
thus suggesting that this shift toward increased CLU2
may mark the transition from the normal to the neoplas-
tic cell phenotype. Specifically, the neoplastic transform-
ation may manifest itself with the alteration of synthesis
of the two CLU transcript variants with a dominance of
CLU2 over CLU1, resulting in the promotion of trans-
formed cell survival. This hypothesis is in agreement
with previous studies suggesting that the survival of
cancer cells is related to over-expression of CLU2 and
down-regulation of CLU1 transcripts [21].
One of the most debated issues in the management of
thyroid nodules is the absence of reliable biomarkers
that can effectively help to identify, among patients car-
rying cytologically indeterminate (TIR3) nodules, those
who necessitate further treatment due to the malignant
nature of their lesion. Currently, the management of
patients carrying thyroid nodules with indeterminate
cytology is limited by the intrinsic limitations of FNAB,
and in such cases the occurrence of abnormal cellular
features preclude a definitive assessment of benignity,
although only a minority will prove malignant upon final
histopathological examination. Consequently, patients
with indeterminate cytopathological reports are com-
monly referred for consideration of hemi- or near-total
thyroidectomy. We attempted to address the potential
usefulness of CLU transcript variants in this context by
measuring the balance between CLU2 and CLU1 in
different cytological categories corresponding to TIR3
and TIR4 + TIR5 samples, classified according to the
SIAPEC. The analysis of CLU transcript variants ex-
pression showed a specific increase of the CLU2 in
TIR3 patients with histologically proven thyroid can-
cer, suggesting a possible diagnostic use of CLU2 in the
management of such patients.
The possible role of CLU in thyroid tumours prognosis
would give more relevance to the results of our paper.
Nevertheless, it is well known that thyroid tumours,
especially the well differentiated types (which are the
majority of our cases) follow a very indolent course and
though we detected a limited number of lymph nodemetastases, their number was not at all adequate to draw
any significant conclusion. The same also applies to
tumour recurrence, which, though present in our series,
were too limited in number to allow statistical analyses
and, above all, seemed more strictly related to tumour
size and extra capsular spread than to Clusterin expres-
sion. Considering this, we decided to skip the analysis of
Clusterin as a potential prognostic marker and focus our
investigation on its role as a diagnostic aid.
Conclusions
Despite the need to further substantiate these results in
a larger and more representative cohort, and albeit the
conclusion are still speculative, they provide new in-
sights into the role of CLU as a pro-survival gene that is
up-regulated in thyroid cancer. We hope this change
may have possible implications for the management of
thyroid cancer to better identify cytological indetermin-
ate lesions to be treated with surgery.
Methods
Patients
This study was carried out in the University Hospital
Policlinico (Bari, Italy) using 65 thyroid tissue specimens
from total thyroidectomies from patients harbouring le-
sions that were 1 cm or more, to make sure that enough
pathological tissue was left from each patient for subse-
quent pathological reporting.
We obtained the participants’ informed consent form
approved by the local ethical committees (AOU Policli-
nico, 70124 Bari, Italy) for their participation and for
publication of the dataset collected at recruitment, in
compliance with international and national data protec-
tion laws. The dataset is fully anonymous, as it does not
contain any direct or indirect identifier, thus respecting
participants’ rights to privacy and identity protection.
Among the 65 total tissues, 50 histological embedded
paraffin thyroid tissues (40 thyroid adenomas, 2 microcar-
cinomas, measuring less than 1 cm, and 8 papillary carcin-
omas, collected from the database of the Department of
Pathology of the University of Bari) were investigated by
immunohistochemistry.
The remaining 15 thyroid tissues (Table 1) were pro-
spectically collected after thyroid surgical resection and
immediately frozen and/or stored at −80°C. All patients
underwent FNAB before surgery. Routinely, each surgi-
cal sample is subjected to intra-operative (i.e., frozen
section) examination to confirm the neoplastic nature of
the lesion and assess the presence of normal adjacent
tissues. Based on the results of intra-operative examin-
ation, the pathologist can obtain fresh samples from
both neoplastic and normal tissues to be used for mo-
lecular analyses. For each patient, biopsy specimens of
normal (N1-N15) and pathological thyroid (K1-K15)
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and the cytological classification according to SIAPEC
(Italian Society Anatomy Pathology and Cytology) [32]
are reported. According to the British Thyroid Associ-
ation, the AACE/AME Task Force on Thyroid Nodules,
the Italian Consensus Working Group and the Bethesda
system for Thyroid Cytopathology, inadequate sampling
was classified as TIR1; benign lesions were categorized
as TIR2; neoplastic/proliferative lesions, characterized by
distinct follicular aggregates without obvious cytological
atypia, as TIR3; lesions that were suspicious for malig-
nancy as TIR4; frankly malignant lesions as TIR5.
As reported in Table 1, 10 patients were affected by
thyroid carcinoma, 4 of the follicular subtype (K5, K6,
K9, K10) and 6 papillary carcinomas (K1-K4, K7-K8)
(median age at surgery: 47 ± 5 years). Their FNAB
yielded the following results: TIR5, n = 3; TIR4, n = 3;
TIR3, n = 4. The remaining 5 patients (K11-K15), were
classified as TIR4 (n = 1) and TIR3 (n = 4) after FNAB
and were affected by non-neoplastic thyroid disease, as
proven at subsequent histological examination.
Histopathology and immunohistochemistry
The surgical samples were fixed in 10% neutral buffered
formalin for 12–24 hours, embedded in paraffin, cut and
stained with Hematoxylin-Eosin.
From the selected cases for which sufficient and repre-
sentative amounts of tissues were available after mor-
phological analysis, a single paraffin block was selected
for immunostaining. Five-μm thick sections were cut,
collected on positively charged slides, de-waxed and re-
hydrated. Following quenching of endogenous peroxid-
ase with 3% H2O2 for 15 minutes at room temperature,
the sections were immunostained for CLU using a
peroxidase-based detection system (En Vision, Dako,
Glostrup, Denmark) with an automated immunostainer
(Autostainer, Dako). Prior to the staining procedure, the
sections to be incubated with anti-CLU antibody were
immersed in 0.01 M citrate buffer, pH 6.0, and incu-
bated at 98°C for 30 minutes in a water bath. Two dis-
tinct mouse monoclonal antibodies identifying α-CLU
were used in this study: clone 41D (provided by Upstate,
Lake Placid, NJ, USA, dilution 1:200) and clone B-5
(provided by Santa Cruz Biotechnology, Santa Cruz, CA,
USA, dilution 1:100) both with 20 minutes incubations
at 37°.
Control sections for antibody specificity included stain-
ing of positive (normal and carcinomatous prostate) as
well as negative sections, which were incubated with the
immunoglobulin fraction of normal mouse serum.
In all cases, the immunoreactivity was independently
evaluated by two pathologists (E. Maiorano and A.
Napoli) by separately counting the relative number
of immunoreactive epithelial cells in 10 differentmicroscopic fields of each case, observed at 40x
magnification.
RNA extraction and qPCR experiments
Frozen tissue samples were pulverized and cellular RNA
was extracted using the Trizol procedure, as previously
described [21]. Quantification of RNA was carried out using
NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE,
USA) spectrophotometer; the quality of RNA was evaluated
on Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA) using a RNA 6000 Nano chip
kit, RNA ladder and Agilent analysis software (Agilent
Technologies).
cDNA synthesis was performed from 1 μg of total
RNA using the QuantiTect® Reverse Transcription kit
(Qiagen). Variant-specific PCRs, using the cDNAs as
templates, were performed using the GoTaq® Flexi DNA
Polymerase (Promega). Variant-specific primer pairs were
constructed with Primer3 software, combining specific
forward primers located in the unique exons 1 (1a, 1b) an-
nealing downstream of the ATG and the reverse primer
located in exon 2. The primer sequences have been previ-
ously listed [21]. Note that the CLU1 amplicon obtained
contains the TATA box sequence suggested by other
authors [11,30] not present in prostate and colon cancer.
1 μl of each cDNA was used as template in qPCR
assays, performed in triplicate with ABI PRISM 7900HT
(Applied Biosystems) using the QuantiTect® SYBR
Green PCR Master Mix (Qiagen). Amplification pa-
rameters have been previously listed [21]. Fluorescence
raw data were exported from the SDS 2.2.1 software
(Applied Biosystems) and analysed with the DART-
PCR Excel workbook [35]. For each tissue, the relative
expression ratio (rER) of different CLU transcripts was
calculated by applying the following formula: [(1 +
E(calibrator))^Ct(calibrator)/ (1 + E(target))^Ct(target)], where
E is the average amplification efficiency calculated by
DART-PCR for each primers pair and Ct is the average
Ct obtained for the calibrator (normal thyroid tissues)
and for the target (all thyroid tissue analysed). More-
over, for each CLU transcript variants the relative
expression ratio (rER) with respect to the analysed
thyroid tissue was calculated by applying the following
formula: [(1 + E(target))^(Ctsample – Ctcalibrator)target]/[(1 +
E(EC)) (Ctsample – Ctcalibrator)EC], where EC is the endogen-
ous control and CLU1 the calibrator. The average data
from at least two independent experiments are reported.
Statistical analysis
Data are reported as the mean ± SEM. Statistical analysis
was performed using the Student’s t-test.
Competing interests
The authors declare that they have no competing interests.
Fuzio et al. BMC Cancer  (2015) 15:349 Page 10 of 10Authors’ contributions
PF designed study; acquired, analysed and interpreted data; drafted
manuscript. AC, SL, AP, FG acquisition of medical data. NN, SL participated in
biological and statistical analyses. AC, EM medical and immunohistological
analyses. EP conceived the study, critically reviewed manuscript for
intellectual content and gave final approval for submission. All authors read
and approved the final version of the manuscript.Acknowledgments
This study was supported by the FIRB-MERIT RBNE08YFN3_005 and
PON01_01297 R&C 2007-2013-VIRTUALAB, by MIUR. The authors thank
Dr. Monica Rutigliano for thyroid tissue samples collection, Dr. Domenica
Lovero for graphical assistance, Giuseppe Cananzi for technical assistance
and Dr. Loredana Moro for useful discussion.
Author details
1Institute of Biomedical Technologies, National Research Council (CNR), Via G.
Amendola, 122/D, 70126 Bari, Italy. 2Department of Emergency and Organ
Transplantation, Section of Pathological Anatomy, University of Bari Aldo
Moro, 70124 Bari, Italy. 3Department of Emergency and Organ
Transplantation, Section of Endocrinology, University of Bari Aldo Moro,
70124 Bari, Italy.
Received: 17 September 2014 Accepted: 22 April 2015References
1. Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL,
Samaan N, editors. Endocrine tumors. Cambridge: Blackwell Scientific; 1993.
p. 278–333.
2. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am.
1990;19:545–76.
3. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol.
2006;94:662–9.
4. Møller MB. Molecular control of the cell cycle in cancer: biological and
clinical aspects. Dan Med Bull. 2003;50:118–38.
5. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic
considerations. Int J Biochem Cell Biol. 1995;27:633–45.
6. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al.
Challenge and promise: roles for clusterin in pathogenesis, progression and
therapy of cancer. Cell Death Differ. 2006;13:12–9.
7. Trougakos IP, Lourda M, Agiostratidou G, Kletsas D, Gonos ES. Differential
effects of clusterin/apolipoprotein J on cellular growth and survival. Free
Radic Biol Med. 2005;38:436–49.
8. Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, et al.
Clusterin facilitates COMMD1 and I-κB degradation to enhance NF-κB
activity in prostate cancer cells. Mol Cancer Res. 2010;8:119–30.
9. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces
G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res.
2004;64:6174–82.
10. Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ.
Clusterin overexpression in both malignant and non-malignant prostate
epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer.
2004;91:1842–50.
11. Prochnow H, Gollan R, Rohne P, Hassemer M, Koch-Brandt C, Baiersdörfer M.
Non-secreted clusterin isoforms are translated in rare amounts from distinct
human mRNA variants and do not affect Bax-mediated apoptosis or the
NF-κB signaling pathway. PLoS One. 2013;8:e75303.
12. Ling IF, Bhongsatiern J, Simpson JF, Fardo DW, Estus S. Genetics of clusterin
isoform expression and Alzheimer’s disease risk. PLoS One. 2012;7:e33923.
13. Moretti RM, Marelli MM, Mai S, Cariboni A, Scaltriti M, Bettuzzi S, et al.
Clusterin isoforms differentially affect growth and motility of prostate cells:
possible implications in prostate tumorigenesis. Cancer Res. 2007;67:10325–33.
14. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK.
Overexpression of clusterin in human breast carcinoma. Am J Pathol.
2000;157:393–9.
15. Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H. Expression of the
secreted form of clusterin protein in renal cell carcinoma as a predictor of
disease extension. BJU Int. 2005;96:895–9.16. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of
different clusterin isoforms in human colon tumorigenesis. Oncogene.
2004;23:2298–304.
17. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, et al. Nucleotide-based
therapies targeting clusterin chemosensitize human lung adenocarcinoma
cells both in vitro and in vivo. Mol Cancer Ther. 2004;3:223–32.
18. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, et al. Enhanced
radiation sensitivity in prostate cancer by inhibition of the cell survival
protein clusterin. Clin Cancer Res. 2002;8:3276–84.
19. Hassan MK, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, et al. Clusterin
is a potential molecular predictor for ovarian cancer patient’s survival:
targeting Clusterin improves response to paclitaxel. J Exp Clin Cancer Res.
2011;113:1–14.
20. Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, et al.
Detection of differentially expressed genes in lymphomas using cDNA
arrays: identification of clusterin as a new diagnostic marker for anaplastic
large-cell lymphomas. Blood. 2000;96:398–404.
21. Fuzio P, Valletti A, Napoli A, Napoli G, Cormio G, Selvaggi L, et al. Regulation
of the expression of CLU isoforms in endometrial proliferative diseases. Int J
Oncol. 2013;42:1929–44.
22. Seol MB, Bong JJ, Baik M. Expression profiles of apoptosis genes in
mammary epithelial cells. Mol Cell. 2005;20:97–104.
23. Miyake H, Hara I, Fujisawa M, Gleave ME. The potential of clusterin inhibiting
antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin
Investig Drugs. 2006;15:507–17.
24. Lemansky P, Brix K, Herzog V. Subcellular distribution, secretion, and
post-translational modifications of clusterin in thyrocytes. Exp Cell Res.
1999;251:147–55.
25. Wegrowski Y, Perreau C, Martiny L, Haye B, Maquart F, Bellon G.
Transforming growth factor β-1 Up-regulates clusterin synthesis in thyroid
epithelial cells. Exp Cell Res. 1999;247:475–83.
26. Kashat L, So A, Masui O, Wang XS, Cao J, Meng X, et al. Secretome based
identification and characterization of potential biomarkers in thyroid cancer.
J Proteome Res. 2010;9:5757–69.
27. Castrignanò T, D’Antonio M, Anselmo A, Carrabino D, D’Onorio De Meo A,
D'Erchia AM, et al. ASPicDB: a database resource for alternative splicing
analysis. Bioinformatics. 2008;24:1300–4.
28. Martelli PL, D’Antonio M, Bonizzoni P, Castrignanò T, D’Erchia AM, D’Onorio
De Meo P, et al. ASPicDB: a database of annotated transcript and protein
variants generated by alternative splicing. Nucleic Acids Res. 2011;39:D80–5.
29. Riva A, Pesole G. A unique, consistent identifier for alternatively spliced
transcript variants. PLoS One. 2009;4:e7631.
30. Schepeler T, Mansilla F, Christensen LL, Ørntoft TF, Andersen CL. Clusterin
expression can be modulated by changes in TCF1-mediated Wnt signaling.
J Mol Signal. 2007;2:1–12.
31. Pucci S, Bettuzzi S. Chapter 3: The shifting balance between CLU forms
during tumour progression. Adv Cancer Res. 2009;104:25–32.
32. Fadda G, Basolo F, Bondi A, Bussolati G, Crescenzi A, Nappi O, et al.
Cytological classification of thyroid nodules. Proposal of the SIAPEC-IAP
Italian Consensus Working Group. Pathologica. 2010;102:405–8.
33. Song HB, Jun HO, Kim JH, Yu YS, Kim KW, Min BH, et al. Anti-apoptotic effect
of clusterin on cisplatin-induced cell death of retinoblastoma cells. Oncol
Rep. 2013;30:2713–8.
34. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer
Staging Manual. 7th ed. New York, NY: Springer; 2010. p. 87–96.
35. Peirson SN, Butler JN, Foster RG. Experimental validation of novel and
conventional approaches to quantitative real-time PCR data analysis. Nucleic
Acids Res. 2003;31:e73.
